PMCF | INVESTMENT BANKING

affiliate of plante moran

MEDICAL TECHNOLOGY M&A PULSE

THIRD QUARTER 2025

OUR INSIGHTS

Medical Technology M&A activity remained subdued in Q3 2025 with 102 announced transactions, essentially flat with the prior quarter. Although well below historical averages, this marks a directional improvement from the consecutive declines that occurred since Q3 2024.

Despite lower transaction volume, deal values remain elevated compared to Q3 2024. Investors continue to pay premiums for specialized businesses that demonstrate resiliency in today's macroeconomic environment.

Looking ahead, increased clarity on tax policy and recent reductions in Federal Reserve interest rates are expected to drive a more favorable M&A environment. These developments restore confidence in selective deal-making, reinforcing long-term optimism for sustained growth in the sector.

IN THIS ISSUE

Medical Technology Coverage Team

BRYAN HUGHES
Managing Director
312.602.3636
bryan.hughes@pmcf.com

MATT JAMISON
Managing Director
312.602.3583
matt.jamison@pmcf.com

MIKE BROOKS
Vice President
312.602.3644
mike.brooks@pmcf.com

ABOUT PMCF

PMCF is an investment bank focused exclusively on middle market transactions with professionals in Chicago, Detroit, Denver, and across the globe through Corporate Finance International™ affiliates. Offering a depth of advisory services, PMCF helps clients worldwide meet their sale, acquisition, financing, and strategic growth objectives. Additional information on PMCF can be found by visiting our website, pmcf.com.

Mergers & Acquisitions	Carve-outs & Divestitures	Strategic Assessments	Capital Raising

MEDICAL TECHNOLOGY INDUSTRY EXPERTISE

In the medical technology sector, it takes a highly focused approach to execute a transaction efficiently. And it requires the constant monitoring of new procedures, technology and product development, and overall market trends. At PMCF, our Medical Technology team brings this dedication and market knowledge to every transaction.

Our transaction expertise in the medical device, bio-pharmaceutical, and healthcare sectors, combined with industry relationships and a proprietary healthcare consulting service offering, afford us a unique perspective in the industry.

Medical Devices	Contract Research	Clinical Services	Therapeutics
Healthcare	Contract Manufacturing	Behavioral Health	Managed Care
Drug Delivery	Bio-Pharmaceutical	Specialty Pharmacy	Specialty Services

SELECT PMCF MEDICAL TECHNOLOGY TRANSACTIONS

rāland
has been acquired by
AKKODiS
a business unit of
Adecco

SVS VISION
has been acquired by
fielmann group

Eagle PHARMACY
has been acquired by
Knipper
a portfolio company of
COURT SQUARE

WRIGHT & FILIPPIS
has been acquired by
ottobock.

Q3 2025 MedTech Market Snapshot

102	Announced transactions, a 38% decline from Q3 2024
10.5x	Average disclosed EV/EBITDA transaction multiple
19.3x	Average public index EV/EBITDA multiple
5.1%	Public index median three-month stock price % change

WHAT WE'RE DISCUSSING WITH CLIENTS

New Policy Dynamics: Accelerating Growth in Medical Technology

Recent legislative changes have created a favorable environment for the Medical Technology industry. The introduction of permanent 100% bonus depreciation allows healthcare providers to immediately expense qualifying equipment purchases, improving cash flow and accelerating capital investment. This incentive is expected to spur upgrades in imaging systems, surgical platforms, and diagnostic technologies, driving demand across the sector. Coupled with enhanced R&D expensing and supportive financing provisions, these dynamics position MedTech companies for stronger organic growth and increased M&A activity, particularly in subsectors offering high-value assets and innovation-driven solutions.

Signals from the Fed: Interest Rate Cuts and their Impact on the MedTech Industry

Interest rate reductions in the second half of 2025 eased financing pressures and reignited momentum in a previously stalled M&A environment. Lower borrowing costs improved access to capital for MedTech companies and private equity firms, making leveraged transactions more attractive and accelerating deal flow. These cuts also supported investment in advanced technologies and infrastructure, creating a stronger backdrop for strategic growth. With rates expected to decline further in 2026, the sector is positioned for an active year of deal-making and expansion, reinforcing confidence in long-term growth prospects.

Medical Technology Sector Description: PMCF defines the Medical Technology sector as companies involved in the development of therapeutic devices, medical equipment, diagnostic tools, and consumable and disposable medical products. It also includes distribution, contract manufacturing, and services that support these products

M&A Activity Summary

Trends in Medical Technology M&A

- M&A activity in the Medical Technology sector remained subdued in Q3 2025 at 102 announced transactions, significantly below the 165 deals recorded in Q3 2024. However, activity was essentially flat compared to Q2 2025, representing a stabilization following consecutive quarterly declines.
- Strategic buyers remained the primary drivers of M&A activity this quarter, accounting for 58% of total deal volume, or 59 transactions.
- Activity was well distributed across subsectors, with the Therapeutic Device segment leading at 26% of total deals. Diagnostic (non-imaging) followed at 15%. The Consumable / Disposable, Contract Manufacturing, Equipment, and Service subsectors were all tied at approximately 11%. This mix reflects a balanced and diversified M&A landscape.

MEDICAL TECHNOLOGY QUARTERLY TRANSACTION VOLUME



SHARE OF MEDICAL TECHNOLOGY M&A TRANSACTION COUNT BY SECTOR



Sources: Capital IQ, PitchBook, Company Reports, PMCF

MEDICAL TECHNOLOGY M&A TRANSACTION METRICS

Period	Mean/Median	Transaction Value ($MM)	TEV/REV	TEV/EBITDA
2025 Q3	Mean	$ 583.39	5.4x	10.5x
2025 Q3	Median	$ 81.25	1.7x	11.0x
2024 Q3	Mean	$ 556.43	2.7x	15.0x
2024 Q3	Median	$ 40.60	1.3x	9.4x
2024	Mean	$ 615.49	4.7x	17.7x
2024	Median	$ 55.30	2.0x	11.2x
2023	Mean	$ 464.93	5.6x	14.1x
2023	Median	$ 45.00	1.8x	9.6x
2022	Mean	$ 463.04	10.0x	27.0x
2022	Median	$ 29.69	2.4x	15.7x

- In Q3 2025, average EV/EBITDA multiples declined to 10.5x, significantly lower than the 15.0x recorded in Q3 2024 and well below recent averages. Average transaction value increased to $583.39 million, representing a $27 million uptick compared to the same period in 2024.
- With lower transaction volumes and higher valuations, buyers are seeking quality over quantity. In the select transactions they pursue, buyers are focused on late-stage targets with companies yet to achieve profitability largely out of consideration.

HEADLINE M&A TRANSACTION METRICS

PATIENT SQUARE CAPITAL

and

PREMIER

September 2025 – Patient Square Capital, a private equity firm with a focus on the healthcare sector, acquired Premier, a healthcare improvement company that offers supply chain and consulting services to healthcare providers

$2.5B	9.0x	2.7x
Enterprise Value	*EV/EBITDA*	*EV/Revenue*

ARCHIMED

and

ZimVie

April 2025 – Archimed SaS, a private equity firm with a focus on the healthcare sector, acquired ZimVie, a therapeutic device manufacturer that produces implants and surgical tools for dental and spine end markets

$813M	16.4x	1.7x
Enterprise Value	*EV/EBITDA*	*EV/Revenue*

Sources: Capital IQ, PitchBook, Company Reports, PMCF

M&A Transaction Segments

M&A Trends by Sector, Geography, and End Market

- Medical Technology subsectors posted varied results in Q3 2025. Therapeutic Device led industry M&A activity with 26 transactions, continuing a trend of growth since the beginning of the year. Other notable increases in activity occurred in Diagnostic (non-imaging), posting 15 transactions, and Distribution, posting 10 transactions. The Service and Equipment subsectors have experienced a prolonged period of contraction, posting 11 transactions each.
- On the geographic front, transaction volume declined for international-only transactions to 47, down from 70 in Q3 2024. Domestic transactions declined to 24, down from 56 in Q3 2024. Cross-border activity slowed as well, but the decline was more gradual compared to foreign and domestic M&A.
- By end market, Equipment was the most active at 17 transactions, followed by Drug Delivery and Orthopedic, which both posted 15 transactions. Compared to Q3 2024, Orthopedic saw the largest growth with 15 transactions, up from 8 in the prior period. Numerous sectors posted declines, with Home Health, Monitor, and Other subsectors coming to a standstill.

QUARTERLY TRANSACTIONS BY SECTOR



CROSS BORDER TRANSACTION TRENDS

Seller-to-Buyer	2022	2023	2024	'24 Q3	'25 Q3
Int'l-to-Int'l	268	258	262	70	47
U.S.-to-Int'l	66	65	55	15	13
U.S.-to-U.S.	196	192	194	56	24
Int'l-to-U.S.	61	54	52	24	18
Total	**591**	**569**	**563**	**165**	**102**

TRANSACTIONS BY END MARKET

End Market	2022	2023	2024	'24 Q3	'25 Q3
Acute Care	8	8	6	2	2
Aesthetic	11	9	17	2	2
Cardiovascular	19	24	41	13	4
Drug Delivery	9	44	81	23	15
Furniture/Equipment	55	47	65	16	17
Home Health	14	12	16	4	-
Hospital Care	23	33	23	3	5
Infection Control	26	16	21	5	3
IVD	29	8	8	2	8
Monitor	21	34	17	12	1
Neurovascular	14	18	12	3	3
Ophthalmology	31	19	23	6	7
Ortho	32	35	38	8	15
Other	64	95	87	24	1
Respiratory	10	13	12	6	2
Support	188	106	52	19	7
Surgical	37	48	44	17	10
Total	**591**	**569**	**563**	**165**	**102**

Sources: Capital IQ, PitchBook, Company Reports, PMCF

Valuation Trends

- The Orthopedic Index outperformed the broader market in Q3 2025 with 14.1% growth compared to the S&P 500 and S&P 500 Growth indices that grew 7.8% and 9.6%, respectively. Diversified Diagnostic and Cardiovascular also posted steady gains. Diversified Medical Device was the weakest performer, declining 4% for the quarter.
- Valuation multiples in the MedTech sector softened in Q3 2025. The median EV/EBITDA multiple declined to 15.1x, reflecting a year-over-year contraction from 15.9x. Further, EV/Revenue multiples declined to 3.7x, down from 4.1x in Q3 2024. At the subsector level, Orthopedic experienced the most significant compression, with valuation multiples dropping 20.9% over the past year. In contrast, the Diversified Medical Device segment remained the most stable, posting only a 0.3% decline.

	Industry and Segment	Stock Price % Change		EV/EBITDA % Change		Current Valuation Stats			Net Debt/ TTM EBITDA
		3 Month	1 Year	3 Month	1 Year	Fwd PE	TTM PE	EV/EBITDA	
Categories	Diversified Medical Device	-4.0%	2.7%	4.6%	-0.3%	20.9x	44.1x	17.7x	2.1x
	Orthopedic	14.1%	-7.5%	-2.5%	-20.9%	14.3x	26.7x	10.1x	3.3x
	Cardiovascular	5.4%	5.8%	-7.2%	-5.7%	26.9x	45.0x	21.2x	3.0x
	Diversified Diagnostic	4.8%	-10.6%	-1.2%	-5.4%	18.1x	30.1x	14.0x	2.5x
	Overall Median	**5.1%**	**-2.4%**	**-1.8%**	**-5.5%**	**19.5x**	**37.1x**	**15.1x**	**2.7x**

PMCF MEDTECH INDEX PUBLIC VALUATIONS [1] [2]

	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue Multiple									
Median	4.1x	4.3x	4.4x	4.1x	4.1x	4.1x	4.0x	3.8x	3.7x
Mean	4.5x	4.6x	5.0x	4.9x	5.0x	4.9x	4.8x	4.7x	4.5x
EBITDA Multiple[1]									
Median	17.1x	17.0x	17.7x	16.1x	15.9x	16.0x	15.0x	15.2x	15.1x
Mean	19.6x	21.0x	20.8x	20.2x	20.9x	22.1x	19.9x	20.8x	19.3x

Q3 2025 CHANGE IN STOCK PRICE[3]



Source: Capital IQ

(1) Multiple of EBITDA based on EBITDA inclusive of equity income from affiliates
(2) Figures based on the last trading day of the period shown
(3) Industry and segment returns are based on price-weighted performance

PMCF Medical Technology Index

Company Name	Headquarters Location	Enterprise Value[1]	Market Cap.[1]	TTM Revenue	TTM Gross Profit	EBITDA	TTM Gross Margin	TTM EBITDA Margin	Net Debt/ EBITDA	EV/ Revenue	EV/EBITDA[2] Q3 '25	EV/EBITDA[2] Q3 '24
$ in Millions [3]												
Diversified Medical Device												
Johnson & Johnson	United States	$478,435	$446,554	$ 92,149	$ 62,988	$ 31,922	68.4%	34.6%	0.9x	5.2x	15.0x	13.4x
Novartis AG	Switzerland	268,974	243,068	56,372	42,982	24,923	76.2%	44.2%	0.9x	4.8x	10.8x	13.6x
Abbott Laboratories	United States	239,569	233,117	43,843	24,666	11,747	56.3%	26.8%	0.4x	5.5x	20.4x	19.3x
Intuitive Surgical, Inc.	United States	155,102	160,321	9,612	6,380	3,412	66.4%	35.5%	NM	16.1x	45.5x	67.8x
Boston Scientific Corporation	United States	156,391	144,663	19,349	13,221	5,071	68.3%	26.2%	2.1x	8.1x	30.8x	32.4x
Stryker Corporation	United States	155,992	141,328	24,381	15,859	6,592	65.0%	27.0%	2.1x	6.4x	23.7x	26.2x
Becton, Dickinson and Company	United States	72,232	53,648	21,840	10,023	5,635	45.9%	25.8%	3.3x	3.3x	12.8x	16.2x
Baxter International Inc.	United States	19,707	11,695	11,023	4,181	2,074	37.9%	18.8%	3.9x	1.8x	9.5x	15.7x
Median							**65.7%**	**26.9%**	**2.1x**	**5.3x**	**17.7x**	**17.8x**
Orthopedic												
Zimmer Biomet Holdings, Inc.	United States	$ 26,686	$ 19,512	$ 8,011	$ 5,738	$ 2,641	71.6%	33.0%	2.6x	3.3x	10.1x	10.8x
Smith & Nephew plc	United Kingdom	18,084	15,361	5,944	4,196	1,436	70.6%	24.2%	1.9x	3.0x	12.6x	13.6x
Globus Medical, Inc.	United States	7,627	7,735	2,770	1,870	770	67.5%	27.8%	NM	2.8x	9.9x	14.9x
Enovis Corporation	United States	3,158	1,734	2,190	1,320	363	60.3%	16.6%	3.9x	1.4x	8.7x	12.8x
Alphatec Holdings, Inc.	United States	2,605	2,152	728	504	5	69.2%	0.7%	NM	3.6x	NM	NM
Orthofix Medical Inc.	United States	717	578	818	562	18	68.6%	2.2%	7.8x	0.9x	39.6x	NM
Median							**68.9%**	**20.4%**	**3.3x**	**2.9x**	**10.1x**	**13.2x**
Cardiovascular												
Medtronic plc	Ireland	$142,871	$122,163	$ 34,200	$ 22,361	$ 9,446	65.4%	27.6%	2.2x	4.2x	15.1x	15.1x
Edwards Lifesciences Corporation	United States	42,355	45,659	5,884	4,600	1,776	78.2%	30.2%	NM	7.2x	23.8x	21.3x
Terumo Corporation	Japan	24,382	24,350	7,194	3,941	1,778	54.8%	24.7%	NM	3.4x	13.7x	18.1x
Merit Medical Systems, Inc.	United States	5,408	4,929	1,477	716	292	48.5%	19.8%	1.5x	3.7x	18.5x	23.7x
Artivion, Inc.	United States	2,208	1,998	423	273	49	64.5%	11.6%	3.9x	5.2x	45.2x	27.1x
LeMaitre Vascular, Inc.	United States	1,847	1,981	241	171	72	71.0%	30.0%	NM	7.7x	25.6x	33.6x
AngioDynamics, Inc.	United States	413	459	301	163	(2)	54.1%	(0.5%)	18.1x	1.4x	NM	NM
Median							**64.5%**	**24.7%**	**3.0x**	**4.2x**	**21.2x**	**22.5x**
Diversified Diagnostic												
Roche Holding AG	Switzerland	$313,460	$279,633	$ 79,831	$ 59,702	$ 29,460	74.8%	36.9%	1.0x	3.9x	10.6x	11.4x
Thermo Fisher Scientific Inc.	United States	212,079	183,149	43,736	18,102	10,835	41.4%	24.8%	3.0x	4.8x	19.6x	24.7x
Danaher Corporation	United States	157,570	141,964	24,268	14,462	7,629	59.6%	31.4%	2.2x	6.5x	20.7x	28.8x
Labcorp Holdings Inc.	United States	29,827	23,855	13,765	3,916	1,964	28.4%	14.3%	3.0x	2.2x	15.2x	14.7x
Quest Diagnostics Incorporated	United States	27,494	21,311	10,850	3,629	2,141	33.4%	19.7%	2.8x	2.5x	12.8x	12.2x
Hologic, Inc.	United States	15,650	15,011	4,101	2,501	1,292	61.0%	31.5%	0.2x	3.8x	12.1x	15.0x
Median							**50.5%**	**28.1%**	**2.5x**	**3.9x**	**14.0x**	**14.8x**
Median							**65.0%**	**26.2%**	**2.2x**	**3.8x**	**15.1x**	**15.9x**
Mean							**60.3%**	**23.9%**	**3.2x**	**4.5x**	**19.3x**	**20.9x**

(1) Market capitalizations and total enterprise values as of September 30, 2025; income statement and balance sheet data as of last period reported

(2) Multiple of EBITDA based on EBITDA inclusive of equity income from affiliates

(3) Currency conversions assume historical rate

Source: Capital IQ

YEAR OVER YEAR % CHANGE IN CPI



The year-over-year (YoY) percentage change in the Consumer Price Index (CPI) reflects the annual rate of inflation by measuring price increases for a standardize basket of goods and services purchased by urban consumers.

As of the end of Q3 2025, the YoY CPI increase was 3.02%, up from 2.43% at the end of Q3 2024, indicating a moderate inflationary environment.

FEDERAL FUNDS RATE



The Federal Funds Rate is the interest rate at which depository institutions lend reserves to one another overnight. As a key benchmark for short-term interest rates, it plays a central role in monetary policy by shaping borrowing costs, consumer spending, and broader economic activity.

As of the end of Q3 2025, the Federal Funds Rate stands at 4.22%, indicating the Federal Reserve is prioritizing maintaining current levels of employment over curbing inflation.

CONSUMER SENTIMENT INDEX



The University of Michigan Consumer Sentiment Index gauges the confidence of U.S. consumers in the health of the economy, based on monthly surveys assessing personal finances, business conditions, and future expectations. It serves as a leading indicator of consumer behavior and overall economic outlook.

As of the end of Q3 2025, the Consumer Sentiment Index stands at 56.1, down considerably from 67 at the end of Q3 2024. This decline is driven by concerns related to the cost of living and forward-looking uncertainty regarding inflation.

Sources: PMCF Research, Federal Reserve Bank of St. Louis, University of Michigan

Venture Capital Activity Overview

The Venture Capital market has seen an uptick in activity and improved sentiment, fueled by clarity on tax policy and additional expected rate cuts before year-end. Although trade policy remains fluid, fears of a recession triggered by a trade war with China have largely subsided. Venture capitalists are cautiously optimistic that improving exit markets will help restart capital recycling, offering relief after years of portfolio challenges. Although some markdowns are still expected, clearer market valuations are enabling better decisions for both investors and founders.

On an annualized basis from Q3 2025, venture capital activity reached 13,181 deals totaling $334 billion in value. This represents a 6% decline in deal volume but a 55% increase in aggregate deal value compared to full-year 2024, driven largely by a handful of outsized transactions. Activity remained evenly distributed across investment stages, with Angel, Early VC, and Late VC representing 32%, 37%, and 31% of Q3 deals, respectively. Medical Technology investments were slightly below historical norms, accounting for 18.7% of total VC activity during the quarter.

Valuations have continued to rise across all stages. Angel and Seed rounds saw modest increases, while Early and Late-stage valuations surged more sharply. On average, valuations are now 48% higher than they were five years ago, fueled by high-profile deals and growing demand for high-quality opportunities.

Investments in Artificial Intelligence and related technologies have grown steadily each year, representing approximately 27% of deal value in 2021 and growing to 49% in 2024 and 64% by 2025. Furthermore, this activity is highly concentrated with only 10 companies in the sector garnering 41% of all VC dollars year-to-date. This dynamic presents a double-edged sword. Although AI has been a catalyst for VC investment, it poses a risk to the industry as many AI startups are yet to achieve profitability and could significantly depress VC returns if enthusiasm for AI wanes.

VC INVESTMENTS IN MEDICAL SECTORS



MEDIAN PRE-MONEY VALUATION BY ROUND



DEAL COUNT BY ROUND



Angel/Seed: The company has a concept or product under development but is likely not fully operational. Typically, in existence less than 18 months.

Early: The company has a product or service in testing or pilot production. In some cases, the product may be commercially available. May or may not be generating revenues. Typically, in business less than three years.

Later: Product or service is widely available. Company is generating ongoing revenue; potentially positive cash flow. More likely to be, but not necessarily, profitable.

**2025 metrics on an annualized basis*

Sources: Capital IQ, PitchBook, Company Reports, PMCF

What is a Strategic Assessment and Why is it Important?

A Strategic Assessment is a comprehensive report that examines a business holistically with specific consideration given to the financial results, operations, and organizational structure. We advise our clients consider one before a planned liquidity event to ensure your company is ready for a transaction. This process includes:

- Determining your company's current value
- Identifying factors that enhance or erode value and related risk considerations
- Developing strategies to bridge gaps in value and market position

7 Reasons Why a Strategic Assessment is Essential for Maximizing Business Value In Preparation of a Liquidity Event

1. Prepares your company for the scrutiny of capital investors
2. Helps ownership and management identify the value attributes and constraints of the business
3. Provides ownership with an understanding of perceived value considerations in the eyes of investors
4. Affords your company an opportunity to address shortfalls and enhance the value in advance of a capital transaction
5. Helps align corporate strategy with organizational, tax, and wealth transfer planning
6. Helps shareholders/management understand how various business strategies can impact future value
7. Resolves potential deal obstacles to ensure a smooth diligence process and higher likelihood of deal success

As an investment in your company, PMCF will complete a complimentary Strategic Assessment.

For additional information, please visit pmcf.com

SIGNIFICANT INDUSTRY EXPERTISE AND RESOURCES

Founded in 1995, PMCF has spent 30 years successfully advising clients in the middle market. From M&A advisory or capital raising to strategic assessment and transaction planning, we execute transactions to achieve life-changing outcomes for our clients. We leverage our significant deal experience, industry relationships, and a deep understanding of sectors we serve to support our clients' organic and inorganic growth initiatives.

PMCF takes a strategic approach to transaction planning, ensuring the positioning and messaging conveys the unique differentiators of your company. Our affiliation with Plante Moran provides us access to transaction tax experts to provide insight into structure planning considerations.

- Developing strategies to effectively deploy capital and resources to maximize ROI on your high-priority growth initiatives
- Aligning your process capabilities with key macrotrends driving industry growth
- Evaluating KPI trends and results and understanding how they are used in daily management
- Reviewing the organizational chart and the internal plan for turnover and/or succession of key management team members
- Pursuing customer diversification at attractive, appropriate margins
- Understanding margin trends and concentrations of margin within product groups or customers
- Assessing your company's differentiation and position in the marketplace
- Leveraging our extensive global relationships to help penetrate new customers and/or markets

About PMCF

OUR LOCATIONS





CHICAGO
10 S. Riverside
9th Floor
Chicago, IL 60606
Phone: 312.602.3600

DETROIT
3000 Town Center
Suite 100
Southfield, MI 48075
Phone: 248.223.3300

DENVER
8181 E. Tufts Avenue
Suite 600
Denver, CO 80237
Phone: 720.370.8181

OUR FIRM

PMCF's M&A advisory and investment banking services are designed to provide company shareholders with a trusted advisor to oversee all transaction related aspects of a company sale or strategic acquisition. Our service levels, industry expertise in Medical Technology, and approach to managing transactions goes well beyond a typical investment banker.

PMCF | INVESTMENT BANKING

- Differentiated approach via senior banker leadership and direct involvement through every step of the transaction providing a consistent and highly experienced point of contact
- One of the largest, most active investment banking boutiques with a focus on specialty niche businesses
- Proven positioning and marketing processes to obtain premium valuations in company sales
- Tailored sale process provides for extensive upfront preparation, detailed company review and identification of any potential issues in advance, and buyer evaluation/diligence ensuring the right fit
- Unique sale planning approach that helps shareholders best prepare for a future sale whether it's six months or several years
- Long-term and client First approach allows PMCF to provide unbiased feedback

Two-time winner, Boutique Investment Banking Firm of the Year by M&A Advisor

Awarded, Cross Border Corporate and Strategic Acquisition of the Year by M&A Advisor

Awarded, Cross Border M&A Deal of the Year by M&A Advisor

Awarded, 2024 Dealmaker of the Year by ACG Detroit

PMCF | INVESTMENT BANKING

10 S Riverside Plaza
9th Floor
Chicago, IL 60606